Protagonist Therapeutics Stock Beneish M Score
| PTGX Stock | USD 25.70 1.15 4.28% |
Protagonist | Beneish M Score |
At this time, it appears that Protagonist Therapeutics is an unlikely manipulator. The earnings manipulation may begin if Protagonist Therapeutics' top management creates an artificial sense of financial success, forcing the stock price to be traded at a high price-earnings multiple than it should be. In general, excessive earnings management by Protagonist Therapeutics executives may lead to removing some of the operating profits from subsequent periods to inflate earnings in the following periods. This way, the manipulation of Protagonist Therapeutics' earnings can lead to misrepresentations of actual financial condition, taking the otherwise loyal stakeholders on to the path of questionable ethical practices and plain fraud.
-2.98
Beneish M Score - Unlikely Manipulator
Protagonist Therapeutics Beneish M-Score Indicator Trends
The cure to earnings manipulation is the transparency of financial reporting. It will typically remove the temptation of the top executives to inflate earnings (i.e., to promote the idea of 'winning at any cost'). Because a healthy internal audit department can enhance transparency, the board should promote the auditors' access to all the record-keeping systems across the enterprise. For example, if Protagonist Therapeutics' auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back.
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Net Receivables | 10.8 M | 10.3 M |
|
| |||||
| Total Assets | 204.1 M | 358 M |
|
| |||||
| Total Current Assets | 196.9 M | 355.6 M |
|
| |||||
| Non Current Assets Total | 2.3 M | 2.4 M |
|
| |||||
| Property Plant Equipment | 2.5 M | 1.8 M |
|
| |||||
| Depreciation And Amortization | 3.5 M | 3.3 M |
|
| |||||
| Selling General Administrative | 18 M | 33.5 M |
|
| |||||
| Total Current Liabilities | 27.7 M | 21.3 M |
|
| |||||
| Short Term Debt | 1.8 M | 1.1 M |
|
| |||||
| Short Term Investments | 99.8 M | 154.9 M |
|
| |||||
| Gross Profit Margin | 0.74 | 0.9448 |
|
|
Protagonist Therapeutics Beneish M-Score Driver Matrix
One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to detect the potential manipulation of earnings. Understanding the correlation between Protagonist Therapeutics' different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards Protagonist Therapeutics in a much-optimized way. Analyzing correlations between earnings drivers directly associated with dollar figures is the most effective way to find Protagonist Therapeutics' degree of accounting gimmicks and manipulations.
Click cells to compare fundamentals
About Protagonist Therapeutics Beneish M Score
M-Score is one of many grading techniques for value stocks. It was developed by Professor M. Daniel Beneish of the Kelley School of Business at Indiana University and published in 1999 under the paper titled The Detection of Earnings Manipulation. The Beneish score is a multi-factor model that utilizes financial identifiers to compile eight variables used to classify whether a company has manipulated its reported earnings. The variables are built from the officially filed financial statements to create a final score call 'M Score.' The score helps to identify companies that are likely to manipulate their profits if they show deteriorating gross margins, operating expenses, and leverage against growing revenue.
Depreciation And Amortization |
|
Protagonist Therapeutics Earnings Manipulation Drivers
Although earnings manipulation is typically not the result of intentional misconduct by the c-level executives, it is still a widespread practice by the senior management of public companies such as Protagonist Therapeutics. It is usually done by a series of misrepresentations of various accounting rules and operating activities across multiple financial cycles. The best way to spot the manipulation is to examine the historical financial statement to find inconsistencies in earning reports to find trends in assets or liabilities that are not sustainable in the future.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Net Receivables | 6.8M | 3.5M | 4.4M | 52K | 10.3M | 10.8M | |
| Total Revenue | 231K | 28.6M | 27.4M | 26.6M | 60M | 63M | |
| Total Assets | 154.9M | 324.5M | 347.7M | 247.9M | 358.0M | 204.1M | |
| Total Current Assets | 145.3M | 315.6M | 340.7M | 237.4M | 355.6M | 196.9M | |
| Net Debt | (16.0M) | (111.4M) | (117.8M) | (122.1M) | (185.6M) | (176.3M) | |
| Short Term Debt | 1.3M | 1.5M | 2.2M | 2.5M | 1.1M | 1.8M | |
| Operating Income | (80.5M) | (64.5M) | (125.8M) | (131.4M) | (93.7M) | (98.3M) | |
| Investments | (52.7M) | (90.5M) | (14.8M) | 92.3M | 26.0M | 27.3M |
About Protagonist Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Protagonist Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Protagonist Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Protagonist Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Protagonist Therapeutics Investors Sentiment
The influence of Protagonist Therapeutics' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Protagonist. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Protagonist Therapeutics' public news can be used to forecast risks associated with an investment in Protagonist. The trend in average sentiment can be used to explain how an investor holding Protagonist can time the market purely based on public headlines and social activities around Protagonist Therapeutics. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Protagonist Therapeutics' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Protagonist Therapeutics' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Protagonist Therapeutics' news discussions. The higher the estimated score, the more favorable is the investor's outlook on Protagonist Therapeutics.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Protagonist Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Protagonist Therapeutics' short interest history, or implied volatility extrapolated from Protagonist Therapeutics options trading.
Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Protagonist Therapeutics using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Check out Protagonist Therapeutics Piotroski F Score and Protagonist Therapeutics Altman Z Score analysis. For more information on how to buy Protagonist Stock please use our How to Invest in Protagonist Therapeutics guide.Note that the Protagonist Therapeutics information on this page should be used as a complementary analysis to other Protagonist Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Complementary Tools for Protagonist Stock analysis
When running Protagonist Therapeutics' price analysis, check to measure Protagonist Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protagonist Therapeutics is operating at the current time. Most of Protagonist Therapeutics' value examination focuses on studying past and present price action to predict the probability of Protagonist Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protagonist Therapeutics' price. Additionally, you may evaluate how the addition of Protagonist Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device |
Is Protagonist Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Protagonist Therapeutics. If investors know Protagonist will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Protagonist Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.39) | Revenue Per Share 1.057 | Quarterly Revenue Growth (1.00) | Return On Assets (0.19) | Return On Equity (0.29) |
The market value of Protagonist Therapeutics is measured differently than its book value, which is the value of Protagonist that is recorded on the company's balance sheet. Investors also form their own opinion of Protagonist Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Protagonist Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Protagonist Therapeutics' market value can be influenced by many factors that don't directly affect Protagonist Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Protagonist Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Protagonist Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Protagonist Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.